Frailty in the Advanced Heart Failure Patient: a Challenging, Neglected, Yet Potentially Modifiable Risk Factor
Source : https://link.springer.com/article/10.1007/s11936-023-00992-7
There is an increasing push for frailty assessment to become a routine part of the evaluation of potential candidates for advanced heart failure (AHF) therapies. The aim of this review...
This review focuses on assessment of frailty specifically in patients with advanced HF, durable mechanical circulatory support, and recipients of heart transplants.
Share
Mean HF score was higher in the worsening HF hospitalization (WHFH) group than in the no WHFH group, even at the beginning of 12 weeks.
Share
Emerging Biomarkers in the Laboratory and in Practice: a Novel Approach to Diagnosing Heart Failure in Diabetes
Source : https://pubmed.ncbi.nlm.nih.gov/38292004/
The Biomarkers for the Diagnosis of Heart Failure in Diabetes webinar was hosted by Diabetes Technology Society on September 20, 2023, with the objective to review current evidence and management...
Experts in HF from clinical chemistry, cardiology, and diabetology present data on screening for HF as an often-unnoticed complication of people with type 1 and type 2 diabetes.
Share
Clinical Characteristics and Outcome of End Stage Hypertrophic Cardiomyopathy: Role of Age and Heart Failure Phenotypes
Source : https://pubmed.ncbi.nlm.nih.gov/38242504/
Two different HCM-ES phenotypes can be recognized, with ES-pEF showing distinctive features at ES recognition and receiving less frequently advanced HF treatments. Older age at ES recognition has a major...
Two different end-stage HCM phenotypes can be recognized, with end-stage pEF showing distinctive features at end-stage recognition and receiving less frequently advanced HF treatments.
Share
Among patients with HFimpEF, treatment with dapagliflozin was associated with lower rates of cardiovascular death relative to placebo, a difference primarily due to lower rates of sudden death.
Share